NKY(SZ:300109) Xin Lang Cai Jing·2025-10-09 01:59Core Viewpoint - The company Xin Kai Yuan has experienced fluctuations in stock price and financial performance, with a notable decrease in revenue and net profit in the first half of 2025 compared to the previous year [2]. Group 1: Stock Performance - As of October 9, Xin Kai Yuan's stock price increased by 2.10%, reaching 18.02 CNY per share, with a trading volume of 40.23 million CNY and a turnover rate of 0.50%, resulting in a total market capitalization of 8.76 billion CNY [1]. - Year-to-date, the stock price has risen by 14.77%, but it has seen a decline of 4.10% over the last five trading days and 3.53% over the last twenty days, while increasing by 9.80% over the last sixty days [1]. - The net inflow of main funds was 1.22 million CNY, with significant buying and selling activities recorded [1]. Group 2: Financial Performance - For the first half of 2025, Xin Kai Yuan reported operating revenue of 644 million CNY, a year-on-year decrease of 12.36%, and a net profit attributable to shareholders of 139 million CNY, down 34.74% year-on-year [2]. - The company has distributed a total of 900 million CNY in dividends since its A-share listing, with 607 million CNY distributed over the past three years [3]. Group 3: Business Overview - Xin Kai Yuan, established on March 13, 2003, and listed on August 25, 2010, is located in Jiaozuo City, Henan Province, and specializes in the research, production, and sales of PVP series products, high-value pharmaceutical excipients, and in vitro diagnostic services [1]. - The main business revenue composition includes: PVP Others 39.57%, PVPK30 Powder 28.35%, Oruisi Series 14.80%, PVP-I 6.85%, Precision Medical Services 3.45%, Early Tumor Diagnosis 3.08%, Gene Testing Technology 3.04%, and Molecular Diagnostic Services 0.87% [1].